drugset / Trial / NCT03344614

A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer

NCT03344614

Phase 2 Unknown 30 enrolled Chinese PLA General Hospital
NaSingle-groupOpen-labelTreatment

Summary

30 patients with advanced colorectal cancer will be enrolled to observe the efficacy and safety of raltitrexed combined with apatinib as a third-line treatment.

Timeline

Start
2017-07-01
Primary completion
2019-01-01
Completion
2019-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Raltitrexed Small molecule 3 mg/m2 Intravenous
Subject Rivoceranib Small molecule 500 mg Oral

Indications